Implication of MATE2, OCT2 and ATM Genes Polymorphism and their Association with Metformin Efficacy and Glycemic Control in Type 2 Diabetes Mellitus Patients
Study shows gene polymorphisms MATE2 and OCT2 affect metformin response in type 2 diabetes, indicating personalized treatment strategies may benefit patients.
Key Points
MATE2 and OCT2 gene polymorphisms significantly influence metformin efficacy and glycemic control.
The GA genotype of MATE2 was associated with a 56% lower odds of metformin response (OR 0.44), while the GG genotype of OCT2 showed a 5.82-fold increase in odds.
Patients were assessed over three months on metformin therapy, recording various glycemic parameters like fasting glucose and HbA1c.
Findings highlight the importance of genetic testing to tailor metformin treatments in type 2 diabetes patients for better outcomes.